Durect Corportion Announces Larsucosterol Phase 3 Trial Design
25 Sep 2024 //
PR NEWSWIRE
DURECT Gets FDA Breakthrough For Larsucosterol In Alcoholic Hepatitis
21 May 2024 //
PR NEWSWIRE
DURECT Corporation Announces Results from Phase 2b Trial of Larsucosterol
07 Nov 2023 //
PR NEWSWIRE
DURECT Announces Last Patient Last Visit in Ph 2b AHFIRM Trial of Larsucosterol
07 Sep 2023 //
PR NEWSWIRE
DURECT concludes patient enrolment in Phase IIb trial of AH therapy
08 Jun 2023 //
CLINICAL TRIALS ARENA
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol
07 Jun 2023 //
PR NEWSWIRE